BioCentury | May 28, 2019
Distillery Therapeutics

Synthetic fusion protein system for EGFR- and HER2-positive cancers

...Epidermal growth factor receptor (EGFR; ErbB1; HER1); HER2 (EGFR2; ErbB2; neu); BCL2-associated X protein (BAX); BH3 interacting domain death agonist (BID)...
BioCentury | Dec 4, 2014
Distillery Therapeutics

Indication: Cancer

...Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Adenomatous polyposis coli (APC); BH3 interacting domain death agonist (BID)...
BioCentury | May 19, 2011
Distillery Therapeutics

Indication: Autoimmune disease

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Inflammatory bowel disease (IBD) BH3 interacting domain death agonist (BID)...
Items per page:
1 - 3 of 3